Puma Biotechnology Company Profile (NYSE:PBYI)

About Puma Biotechnology (NYSE:PBYI)

Puma Biotechnology logoPuma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $2.95 billion
  • Outstanding Shares: 36,966,000
Average Prices:
  • 50 Day Moving Avg: $40.53
  • 200 Day Moving Avg: $38.27
  • 52 Week Range: $27.64 - $80.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.74
  • P/E Growth: 0.02
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $4.53 per share
  • Price / Book: 17.60
Profitability:
  • EBIDTA: ($277,330,000.00)
  • Return on Equity: -179.99%
  • Return on Assets: -141.40%
Debt:
  • Current Ratio: 3.12%
  • Quick Ratio: 3.12%
Misc:
  • Average Volume: 1.63 million shs.
  • Beta: 0.35
  • Short Ratio: 5.91
 

Frequently Asked Questions for Puma Biotechnology (NYSE:PBYI)

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBYI."

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology Inc (NYSE:PBYI) posted its quarterly earnings results on Wednesday, May, 10th. The company reported ($1.97) EPS for the quarter, beating the Zacks' consensus estimate of ($2.06) by $0.09. View Puma Biotechnology's Earnings History.

Where is Puma Biotechnology's stock going? Where will Puma Biotechnology's stock price be in 2017?

7 brokers have issued 12-month target prices for Puma Biotechnology's shares. Their forecasts range from $60.00 to $91.00. On average, they anticipate Puma Biotechnology's share price to reach $84.57 in the next year. View Analyst Ratings for Puma Biotechnology.

Are investors shorting Puma Biotechnology?

Puma Biotechnology saw a increase in short interest in April. As of April 28th, there was short interest totalling 7,945,184 shares, an increase of 2.1% from the April 13th total of 7,784,785 shares. Based on an average trading volume of 976,527 shares, the days-to-cover ratio is currently 8.1 days.

Who are some of Puma Biotechnology's key competitors?

Who owns Puma Biotechnology stock?

Puma Biotechnology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (9.58%), Wellington Management Group LLP (6.87%), Vanguard Group Inc. (6.57%), Janus Capital Management LLC (5.98%), Redmile Group LLC (4.67%) and State Street Corp (4.06%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.

Who sold Puma Biotechnology stock? Who is selling Puma Biotechnology stock?

Puma Biotechnology's stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., State Street Corp, Morgan Stanley, UBS Group AG, Oxford Asset Management, Bank of New York Mellon Corp, TIAA CREF Investment Management LLC and Ameriprise Financial Inc.. Company insiders that have sold Puma Biotechnology stock in the last year include Adage Capital Partners Gp, LL, Alan H Auerbach, Richard Paul Bryce and Robert Charnas. View Insider Buying and Selling for Puma Biotechnology.

Who bought Puma Biotechnology stock? Who is buying Puma Biotechnology stock?

Puma Biotechnology's stock was bought by a variety of institutional investors in the last quarter, including Camber Capital Management LLC, Redmile Group LLC, Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Renaissance Technologies LLC, Wellington Management Group LLP, Schroder Investment Management Group and Vanguard Group Inc.. View Insider Buying and Selling for Puma Biotechnology.

How do I buy Puma Biotechnology stock?

Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Puma Biotechnology stock cost?

One share of Puma Biotechnology stock can currently be purchased for approximately $79.75.

Analyst Ratings

Consensus Ratings for Puma Biotechnology (NYSE:PBYI) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $84.57 (6.05% upside)

Analysts' Ratings History for Puma Biotechnology (NYSE:PBYI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Credit Suisse Group AGBoost Price TargetOutperform$58.00 -> $90.00LowView Rating Details
5/25/2017Cowen and CompanyUpgradeNeutral -> Outperform$91.00LowView Rating Details
5/25/2017Bank of America CorpBoost Price TargetBuy$72.00 -> $86.00LowView Rating Details
5/25/2017Royal Bank of CanadaBoost Price TargetSector Perform -> Sector Perform$40.00 -> $60.00LowView Rating Details
5/24/2017JPMorgan Chase & Co.Reiterated RatingOverweight$89.00MediumView Rating Details
5/22/2017Citigroup IncReiterated RatingBuy$88.00HighView Rating Details
5/22/2017Stifel NicolausReiterated RatingBuy$88.00HighView Rating Details
1/5/2016Berenberg BankUpgradeHold -> BuyN/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Puma Biotechnology (NYSE:PBYI)
Earnings by Quarter for Puma Biotechnology (NYSE:PBYI)
Earnings History by Quarter for Puma Biotechnology (NYSE:PBYI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($2.06)($1.97)ViewN/AView Earnings Details
3/1/2017Q4($1.92)($2.04)ViewN/AView Earnings Details
5/10/2016Q1($1.99)($1.28)ViewN/AView Earnings Details
2/29/2016Q4($1.95)($1.23)ViewN/AView Earnings Details
11/9/2015Q3($1.84)($1.87)ViewN/AView Earnings Details
8/10/2015Q2($1.55)($1.13)ViewN/AView Earnings Details
5/11/2015Q1($1.25)($1.02)ViewN/AView Earnings Details
3/2/2015($1.15)($1.59)ViewN/AView Earnings Details
11/10/2014($1.27)($1.19)ViewN/AView Earnings Details
8/11/2014Q214($0.66)($1.05)ViewN/AView Earnings Details
5/12/2014($0.48)($0.67)ViewN/AView Earnings Details
3/3/2014Q413($0.49)($0.46)ViewN/AView Earnings Details
4/1/2013Q413($0.70)($0.25)ViewN/AView Earnings Details
11/14/2012Q312($1.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Puma Biotechnology (NYSE:PBYI)
Current Year EPS Consensus Estimate: $-8.32 EPS
Next Year EPS Consensus Estimate: $-4.04 EPS

Dividends

Dividend History for Puma Biotechnology (NYSE:PBYI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Puma Biotechnology (NYSE:PBYI)
Insider Ownership Percentage: 22.70%
Institutional Ownership Percentage: 80.98%
Insider Trades by Quarter for Puma Biotechnology (NYSE:PBYI)
Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)
Insider Trades by Quarter for Puma Biotechnology (NYSE:PBYI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,235,700$75.38$93,147,066.00View SEC Filing  
2/1/2017Robert CharnasInsiderSell3,008$31.83$95,744.64View SEC Filing  
1/20/2017Alan H AuerbachInsiderSell10,202$33.24$339,114.48View SEC Filing  
1/20/2017Richard Paul BryceSVPSell2,293$33.24$76,219.32View SEC Filing  
7/6/2015Richard Paul BryceSVPSell3,000$110.03$330,090.00View SEC Filing  
11/8/2013Adage Capital Partners Gp Llcmajor shareholderBuy22,549$38.92$877,607.08View SEC Filing  
11/5/2013Adage Capital Partners Gp Llcmajor shareholderBuy280,700$39.60$11,115,720.00View SEC Filing  
10/9/2013Adage Capital Partners Gp Llcmajor shareholderBuy140,900$40.44$5,697,996.00View SEC Filing  
12/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy29,560$19.00$561,640.00View SEC Filing  
12/12/2012Adage Capital Partners Gp LlcMajor ShareholderBuy30,400$19.00$577,600.00View SEC Filing  
12/11/2012Adage Capital Partners Gp LlcMajor ShareholderBuy140,040$18.98$2,657,959.20View SEC Filing  
10/24/2012Thomas MalleyDirectorBuy10,000$16.00$160,000.00View SEC Filing  
10/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy610,000$16.00$9,760,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Puma Biotechnology (NYSE:PBYI)
Latest Headlines for Puma Biotechnology (NYSE:PBYI)
Source:
DateHeadline
benzinga.com logoPuma Biotech Gets Favorable FDA Vote On Neratinib - Benzinga
www.benzinga.com - May 27 at 1:24 AM
rttnews.com logoPuma Biotechnology Inc. (PBYI) Broke Out To A New High After FDA Vote
www.rttnews.com - May 26 at 8:22 PM
finance.yahoo.com logoPuma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session
finance.yahoo.com - May 26 at 8:22 PM
finance.yahoo.com logoWill Puma Biotechnology (PBYI) Continue to Surge Higher?
finance.yahoo.com - May 26 at 8:22 PM
finance.yahoo.com logoPuma Soaring After Neratinib FDA Panel Win, Time to Buy?
finance.yahoo.com - May 26 at 8:22 PM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Major Shareholder Adage Capital Partners Gp, L.L Sells 1,235,700 Shares
www.americanbankingnews.com - May 26 at 7:24 PM
americanbankingnews.com logoStock Traders Purchase High Volume of Call Options on Puma Biotechnology (PBYI)
www.americanbankingnews.com - May 26 at 7:52 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Stock Rating Upgraded by Cowen and Company
www.americanbankingnews.com - May 25 at 7:26 PM
americanbankingnews.com logoCredit Suisse Group AG Reaffirms Outperform Rating for Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - May 25 at 7:26 PM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Given "Buy" Rating at Bank of America Corp
www.americanbankingnews.com - May 25 at 6:11 PM
feeds.benzinga.com logoIs The FDA Panel Vote On Puma Biotech Likely To Lead To Actual Approval?
feeds.benzinga.com - May 25 at 3:23 PM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Price Target Raised to $60.00
www.americanbankingnews.com - May 25 at 1:52 PM
feeds.benzinga.com logoPuma Biotech 'Is The Real Deal,' Overcomes Controversy With Positive FDA Panel Vote
feeds.benzinga.com - May 25 at 12:16 PM
investorplace.com logoPuma Biotechnology Inc (PBYI) Pops 60% on FDA Review - Investorplace.com
investorplace.com - May 25 at 12:24 AM
americanbankingnews.com logoPuma Biotechnology's (PBYI) Overweight Rating Reiterated at JPMorgan Chase & Co.
www.americanbankingnews.com - May 24 at 11:26 PM
nasdaq.com logoU.S. FDA panel backs Puma Biotech's breast cancer drug
www.nasdaq.com - May 24 at 7:23 PM
streetinsider.com logoPuma Biotech (PBYI) Confirms FDA AdCom Backing for Neratinib
www.streetinsider.com - May 24 at 7:23 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017
finance.yahoo.com - May 24 at 7:23 PM
finance.yahoo.com logoFDA Panel Votes 12 To 4 to Approve Puma's Breast Cancer Drug
finance.yahoo.com - May 24 at 7:23 PM
finance.yahoo.com logoPuma Biotechnology Receives FDA Advisory Committee Support for Neratinib
finance.yahoo.com - May 24 at 7:23 PM
finance.yahoo.com logoPuma Biotech Gets Favorable FDA Vote On Neratinib
finance.yahoo.com - May 24 at 7:23 PM
finance.yahoo.com logoPuma Biotech shares surge 20% after FDA advisory committee votes in favor of approving breast cancer drug
finance.yahoo.com - May 24 at 7:23 PM
finance.yahoo.com logoWhy Abercrombie & Fitch, Triumph Group, and Puma Biotechnology Jumped Today
finance.yahoo.com - May 24 at 7:23 PM
finance.yahoo.com logoThis Biotech Stock Has Soared 84% This Week On Breast-Cancer Drug News
finance.yahoo.com - May 24 at 7:22 PM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 24 at 12:10 PM
fool.com logoWhy Puma Biotechnology Inc Jumped Higher Today - Motley Fool
www.fool.com - May 24 at 10:09 AM
finance.yahoo.com logoPuma Biotechnology FDA Live Blog
finance.yahoo.com - May 24 at 10:09 AM
americanbankingnews.com logoCredit Suisse Group AG Analysts Give Puma Biotechnology Inc (PBYI) a $58.00 Price Target
www.americanbankingnews.com - May 23 at 8:04 PM
feeds.benzinga.com logoHere's Why Wednesday Is The Next Big Catalyst For Puma Biotech
feeds.benzinga.com - May 23 at 12:43 PM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 23 at 12:36 PM
rttnews.com logoPuma Biotechnology Inc. (PBYI) Surged To A 6-Month High
www.rttnews.com - May 23 at 9:57 AM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Short Interest Up 2.1% in April
www.americanbankingnews.com - May 23 at 7:10 AM
americanbankingnews.com logoPuma Biotechnology's (PBYI) "Buy" Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - May 22 at 8:22 PM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Given Buy Rating at Citigroup Inc
www.americanbankingnews.com - May 22 at 8:22 PM
americanbankingnews.com logoPuma Biotechnology Inc (PBYI) Earns "Market Perform" Rating from Cowen and Company
www.americanbankingnews.com - May 22 at 8:22 PM
americanbankingnews.com logoInvestors Purchase Large Volume of Put Options on Puma Biotechnology (PBYI)
www.americanbankingnews.com - May 22 at 6:30 PM
streetinsider.com logoPuma Biotech (PBYI) Confirms Posting of FDA Briefing Documents for Neratinib Panel
www.streetinsider.com - May 22 at 6:20 PM
finance.yahoo.com logoPuma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting
finance.yahoo.com - May 22 at 6:20 PM
finance.yahoo.com logoPuma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote
finance.yahoo.com - May 22 at 6:20 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 - PBYI
finance.yahoo.com - May 22 at 6:20 PM
finance.yahoo.com logoPuma Biotech Shares Are Roaring On An FDA Review. Here's What Could Still Go Wrong
finance.yahoo.com - May 22 at 6:20 PM
finance.yahoo.com logoPuma Biotech Surges To 6-Month High On Likely Cancer Drug Approval
finance.yahoo.com - May 22 at 6:20 PM
fool.com logoWhy Puma Biotechnology Inc Jumped Higher Today
www.fool.com - May 22 at 1:34 PM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Puma (PBYI) Stock?
finance.yahoo.com - May 22 at 9:40 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline – PBYI
finance.yahoo.com - May 22 at 9:40 AM
prnewswire.com logoPUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT ... - PR Newswire (press release)
www.prnewswire.com - May 20 at 11:43 PM
prnewswire.com logoHarwood Feffer LLP Announces Investigation of Puma Biotechnology, Inc. - PR Newswire (press release)
www.prnewswire.com - May 20 at 11:43 PM
seekingalpha.com logoPuma Biotechnology (PBYI) Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 19 at 7:43 PM
finance.yahoo.com logoHarwood Feffer LLP Announces Investigation of Puma Biotechnology, Inc.
finance.yahoo.com - May 19 at 7:43 PM
finance.yahoo.com logoPBYI INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017
finance.yahoo.com - May 19 at 11:56 AM

Social

Chart

Puma Biotechnology (PBYI) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff